Long‐term outcomes of switching to aflibercept for treatment‐resistant neovascular age‐related macular degeneration

Abstract

Aflibercept is an effective alternative therapy for treatment-resistant nAMD. Good anatomical and stable functional responses are achievable with continued therapy. The lack of continued visual improvement may be representative of GA progression, reflecting the progression of late-stage nAMD in these patients.